Piramal Enterprises eyes at acquisition of multiple pharma assets, plans come back into domestic formulations
Piramal Enterprises Ltd (PEL) is looking at multiple acquisition opportunities across its pharma business, including a possible re-entry into domestic formulations, which the company exited in 2010.
The company, in its FY21 annual report, said that it is looking at acquisitions of niche manufacturing capabilities for a Contract Development and Manufacturing Organisation (CDMO).
A CDMO is a company that serves other companies in the pharmaceutical industry on a contract basis to provide comprehensive services from drug development to manufacturing.
It is also looking at adding new complex hospital generics through in-licensing, acquisitions, and capital investments, and organic and inorganic addition of consumer healthcare products to leverage the pan-India distribution platform and explore re-entry into domestic formulations.